These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 15671559)
21. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Sève P; Reiman T; Isaac S; Trillet-Lenoir V; Lafanéchère L; Sawyer M; Dumontet C Anticancer Res; 2008; 28(2B):1161-7. PubMed ID: 18505052 [TBL] [Abstract][Full Text] [Related]
22. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860 [TBL] [Abstract][Full Text] [Related]
23. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408 [TBL] [Abstract][Full Text] [Related]
24. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221 [TBL] [Abstract][Full Text] [Related]
25. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Ranganathan S; McCauley RA; Dexter DW; Hudes GR Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260 [TBL] [Abstract][Full Text] [Related]
26. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Hiser L; Aggarwal A; Young R; Frankfurter A; Spano A; Correia JJ; Lobert S Cell Motil Cytoskeleton; 2006 Jan; 63(1):41-52. PubMed ID: 16362954 [TBL] [Abstract][Full Text] [Related]
27. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891 [TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Zhang T; Guan M; Jin HY; Lu Y Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151 [TBL] [Abstract][Full Text] [Related]
29. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Banerjee A Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644 [TBL] [Abstract][Full Text] [Related]
30. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470 [TBL] [Abstract][Full Text] [Related]
31. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Penson RT; Oliva E; Skates SJ; Glyptis T; Fuller AF; Goodman A; Seiden MV Gynecol Oncol; 2004 Apr; 93(1):98-106. PubMed ID: 15047220 [TBL] [Abstract][Full Text] [Related]
32. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615 [TBL] [Abstract][Full Text] [Related]
33. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446 [TBL] [Abstract][Full Text] [Related]
35. beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. Gréen H; Rosenberg P; Söderkvist P; Horvath G; Peterson C Cancer Lett; 2006 May; 236(1):148-54. PubMed ID: 16002208 [TBL] [Abstract][Full Text] [Related]
36. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Gan PP; Pasquier E; Kavallaris M Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044 [TBL] [Abstract][Full Text] [Related]
37. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099 [TBL] [Abstract][Full Text] [Related]
38. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Verdier-Pinard P; Wang F; Burd B; Angeletti RH; Horwitz SB; Orr GA Biochemistry; 2003 Oct; 42(41):12019-27. PubMed ID: 14556633 [TBL] [Abstract][Full Text] [Related]
39. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Wehbe H; Kearney CM; Pinney KG Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172 [TBL] [Abstract][Full Text] [Related]
40. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]